Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial

Journal of Infectious Diseases

Volumn 171, Issue 2, 1995, Pages 305-311

  Fiscus, Susan A ^{a,b,c,d,e,f,g,h}   De Gruttola, Victor ^{a,b,c,d,e,f,g,h}   Gupta, Phalguni ^{a,b,c,d,e,f,g,h}   Katzenstein, David A ^{a,b,c,d,e,f,g,h}   Meyer, William A ^{a,b,c,d,e,f,g,h}   Lo Faro, Marsha L ^{a,b,c,d,e,f,g,h}   Katzman, Michael ^{a,b,c,d,e,f,g,h}   Ragni, Margaret V ^{a,b,c,d,e,f,g,h}   Reichelderfer, Patricia S ^{a,b,c,d,e,f,g,h}   Coombs, Robert W ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Maryland Medical Laboratories Inc   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS CULTURE;

CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMAN; LEUKOCYTES, MONONUCLEAR; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT OUTCOME; VIRUS CULTIVATION; ZIDOVUDINE;

EID: 0028855313     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.2.305     Document Type: Article

References (36)

1. Jackson JB, Coombs RW, Sannerud K, Rhame FS, Balfour HH Jr. Rapid and sensitive viral culture method for human immunodeficiency virus type I. J Clin Microbiol 1988;26:1416-8
2. Castro BA. Weiss CD, Wiviott D, Levy JA. Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol 1988;26:2371-6
3. Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31
4. Gupta P, Enrico A, Armstrong J. Doerr M, Ho M, Rinaldo C. A semi quantitative microassay for measurement of relative number of blood mononuclear cells infected with human immunodeficiency virus. AIDS Res Hum Retroviruses 1990;6:1193-6
5. Erice A, Sannerud KJ, Leske VL, Aeppli D, Balfour HH Jr. Sensitive microculture method for isolation of human immunodeficiency virus type-1 from blood leukocytes. J Clin Microbiol 1992;30:444-8
6. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5
7. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, et al. Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990; 113:438-43
8. Connor RI, Mohri H, Cao YZ, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type I-infected individuals. J Virol 1993;67:1772-7
9. Chaisson RE, Leather MD, Allain JP, et al. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Arch Intern Med 1988;148:2151-3
10. Volherding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9
11. Choi SS, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80
12. DeCruttola V, Beckett LA, Coombs RW, et al. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type I. J Infect Dis 1994;169:713-21
13. DeGruttola V, Wulfsohn M, Fischl M, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993;6:359-65
14. Calvelli T. Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases. Division of AIDS. Cytometry 1993;14:702-15
15. Gelman R, Cheng SC, Kidd P, Waxda! M, Kagan J. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. Clin Immunol Immunopathol 1993:66:150-62
16. Hollinger FB, Bremer JW, Myers LE. Gold JWM, McQuay L. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS clinical trials group. J Clin Microbiol 1992;30:1787-94
17. Hollinger FB, ed. ACTG virology manual for HIV laboratories. 2nd ed. Bethesda, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 1993; publication no. NIH-94-3828
18. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994;32:732-9
19. Coombs RW, Henrard DR, Mehaffey WF, et al. Cell-free plasma human immunodeficiency virus type-1 titer assessed by culture and immunocapture-reverse transcription—polymerase chain reaction. J Clin Microbiol 1993;31:1980-6
20. Nishanian P. Huskins KR. Stehn S, Detels R, Fahey JL. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990;162:21-8
21. Cox DR, Hinkley DV. Theoretical statistics. London: Chapman and Hall, 1974
22. SAS user's guide. Cary. NC: SAS Institute. 1982
23. Pan LZ, Werner A, Levy JA. Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. J Clin Microbiol 1993;31:283-8
24. Vernazza PL, Eron JJ, Fiscus S. Loss of infectivity ex vivo in plasma of human immunodeficiency virus-infected patients correlates with a high CD4 cell count. J Infect Dis 1993;168:1269-72
25. Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990;323:1015-21
26. Merigan TC, Clark G, Katzenstein DA, Holodniy M. Correlation be tween human immunodeficiency virus (HIV) load, stage of disease, and dideoxy drug administration using quantitative RNA and DNA polymerase chain reaction (PCR) and viremia measurements. In: Andrieu JM, Cramer P, eds. Viral quantitation in HIV infection. Paris: Libbey Eurotext, 1992:147-52
27. Holodniy M, Katzenstein D, Winters M, et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acqir Immune Defic Syndr 1993;6:366-9
28. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HI V-1 infection. Ann Intern Med 1993;119:786-93
29. Shepp DH, Ashraf A. Effect of didanosine on human immunodeficiency virus viremia and antigenemia in patients with advanced disease—correlation with clinical response. J Infect Dis 1993:167:305
30. Coombs RW, Collier AC, Corey L. Plasma viremia as an endpoint in evaluating the effectiveness of drugs against human immunodeficiency virus type-1 (HIV) infection: natural history of plasma viremia and monitoring of antiretroviral therapy. In: Andrieu JM, Cramer P, eds. Viral quantitation in HIV infection. Paris: Libbey Eurotext, 1992:9-19
31. Paxton WB, Coombs RW, Aung S, Williams B, McElrath J, Corey L. HIV viral and proviral load in asymptomatic HIV-infected persons (abstract 1255). In: Program and abstracts of the 33rd Interscience Congress on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993:349
32. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type-1 RNA. J Infect Dis 1994;170:553-62
33. Hammer S, Crumpacker C, D'Aquila R, et al. Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS clinical trials group virology committee. J Clin Microbiol 1993;31:2557-64
34. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8
35. Embretson J, Zupancic M, Ribas JL., et al. Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62
36. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-8